Does PEMBROLIZUMAB Cause Immune-mediated hepatitis? 549 Reports in FDA Database
Boost Your Natural Energy & Metabolism
Mitolyn — 6 exotic plants to unlock your body's fat-burning power. 90-day guarantee.
According to the FDA Adverse Event Reporting System (FAERS), 549 reports of Immune-mediated hepatitis have been filed in association with PEMBROLIZUMAB (KEYTRUDA). This represents 0.7% of all adverse event reports for PEMBROLIZUMAB.
549
Reports of Immune-mediated hepatitis with PEMBROLIZUMAB
0.7%
of all PEMBROLIZUMAB reports
101
Deaths
318
Hospitalizations
How Dangerous Is Immune-mediated hepatitis From PEMBROLIZUMAB?
Of the 549 reports, 101 (18.4%) resulted in death, 318 (57.9%) required hospitalization, and 66 (12.0%) were considered life-threatening.
Is Immune-mediated hepatitis Listed in the Official Label?
Yes, Immune-mediated hepatitis is listed as a known adverse reaction in the official FDA drug label for PEMBROLIZUMAB.
What Other Side Effects Does PEMBROLIZUMAB Cause?
Malignant neoplasm progression (10,111)
Death (4,744)
Diarrhoea (4,251)
Fatigue (3,833)
Off label use (3,416)
Product use in unapproved indication (3,191)
Pyrexia (3,155)
Rash (2,900)
Nausea (2,670)
Decreased appetite (2,486)
What Other Drugs Cause Immune-mediated hepatitis?
NIVOLUMAB (640)
IPILIMUMAB (443)
CARBOPLATIN (213)
PACLITAXEL (167)
ATEZOLIZUMAB (142)
BEVACIZUMAB (108)
DURVALUMAB (90)
LENVATINIB (86)
PEMETREXED (86)
TREMELIMUMAB (51)
Which PEMBROLIZUMAB Alternatives Have Lower Immune-mediated hepatitis Risk?
PEMBROLIZUMAB vs PEMETREXED
PEMBROLIZUMAB vs PEMIGATINIB
PEMBROLIZUMAB vs PENICILLAMINE
PEMBROLIZUMAB vs PENICILLIN
PEMBROLIZUMAB vs PENICILLIN G